Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-05-10
2009-12-29
Low, Christopher S. F. (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S04400A, C435S375000
Reexamination Certificate
active
07638482
ABSTRACT:
The present invention is based on the discovery that ζPKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased ζPKC gene expression in arthritic tissue. The present invention further provides compounds that inhibit the expression of ζPKC for use as remedies in the treatment of arthritis, including, but not limited to, inhibitory polynucleotides and polypeptides, small molecules, and peptide inhibitors. In addition, the present invention provides pharmaceutical formulations and routes of administration for such remedies, as well as methods for assessing their efficacy.
REFERENCES:
patent: 5565448 (1996-10-01), Nambi et al.
patent: 6368831 (2002-04-01), Maurer et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6608105 (2003-08-01), Asakawa et al.
patent: 2003/0105075 (2003-06-01), Meijer
patent: WO 0100229 (2001-01-01), None
Goldring et al. Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J Clin Invest. vol. 94, No. 6, pp. 2307-2316, Dec. 1994.
Theiler et al. Clinical, biochemical and imaging methods of assessing osteoarthritis and clinical trials with agents claiming , ‘chondromodulating’ activity. Osteoarthritis Cartilage. vol. 2, No. 1, pp. 1-23, Mar. 1994.
Lequesne et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol Suppl. Supplement 41, pp. 65-71, Sep. 1994.
Fajardo et al. Disease-modifying therapies for osteoarthritis : current status. Drugs Aging. vol. 22, No. 2, pp. 141-161, 2005.
Toullec et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. vol. 266, No. 24, pp. 15771-15781, Aug. 1991.
van den Berg. Lessons from animal models of osteoarthritis. Curr Opin Rheumatol. vol. 13, No. 5, pp. 452-456, Sep. 2001.
LaVallie et al. Protein kinase Czeta is up-regulated in osteoarthritic cartilage and is required for activation of NF-kappaB by tumor necrosis factor and interleukin-1 in articular chondrocytes. The Journal of Biological Chemistry, vol. 281, No. 34, pp. 24124-21437, Aug. 2006.
Hamanishi et al. Protein kinase C activator inhibits progression of osteoarthritis induced in rabbit knee joints. J Lab Clin Med, vol. 127, No. 6, pp. 540-544, Jun. 1996.
Thiam et al. Direct evidence of cytoplasmic delivery of PKC-alpha, -epsilon and -zeta pseudosubstrate lipopeptides: study of their implication in the induction of apoptosis. FEBS Letters, vol. 459, pp. 285-290, Oct. 1999.
Piperno et al. Osteoarthritic cartilage fibrillation is associated with a decrease in chondrocyte adhesion to fibronectin. Osteoarthritis Cartilage. vol. 6, No. 6, pp. 393-399, Nov. 1998.
Kim et al. p38 kinase-dependent and -independent inhibition of protein kinase c zeta and alpha regulates nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes. JBC Papers in Press, Published online on Jun. 4, 2002 as manuscript M205193200.
Saraiva et al. Isoform-selectivity of PKC inhibitors acting at the regulatory and catalytic domain of mammalian PKC-alpha, -betal, -delta, -eta, and -zeta. Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 18, No. 6, pp. 475-483, Dec. 2003.
Bonnet et al. Synthesis by chemoselective ligation and biological evaluation of novel cell-permeable PKC-Zeta pseudosubstrate lipopeptides. J. Med. Chem. vol. 44, pp. 468-471, 2001.
Vuolteenaho et al. Effects of TNFalpha-antagonists on nitric oxide production in human cartilage. Osteoarthritis and Cartilage, vol. 10, pp. 327-332, Apr. 2002.
Alden et al., “In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector,” Hum. Gene Ther., vol. 10, pp. 2245-2253 (1999).
Arts et al., “Adenoviral Vectors Expressing siRNAs for Discovery and Validation of Gene Function,” Genome Res., vol. 13, pp. 2325-2332 (2003).
Bandyopadhyay et al., “Activation of protein kinase C (α, β, and ζ) by insulin in 3T3/L1 cells. Transfection studies suggest a role for PKC-ζ in glucose transport,” J. Biol. Chem., vol. 272, pp. 2551-2558 (1997).
Bass, “RNA Interference. The Short Answer,” Nature, vol. 411, No. 6836, pp. 428-429 (May 2001).
Bond et al., “Inhibition of transcription factor NF-κB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells,” Cardiovasc. Res., vol. 50, pp. 556-565 (2001).
Bond et al., “Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts,” Biochem. Biophys. Res. Commun., vol. 264, pp. 561-567 (1999).
Bond et al., “Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB,” FEBS Lett., vol. 435, pp. 29-34 (1998).
Catterall and Cawston, “Drugs in development: bisphosphonates and metalloprotelnase inhibitors,” Arthritis. Res. Ther., vol. 5, pp. 12-24 (2003).
Dang et al., “Protein kinase C ζ phosphorylates a subset of selective sites of the NADPH oxidase component p47phox and participates in formyl peptide-mediated neutrophil respiratory burst,” J. Immunol., vol. 166, pp. 1206-1213 (2001).
Diaz-Meco et al., “The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C,” Cell, vol. 86, pp. 777-786 (1996).
Dorn et al., “siRNA relieves chronic neuropathic pain,” Nucleic Acids Res., vol. 32 (5), p. e49 (2004).
Elbashir et al., “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,” Nature, vol. 411, pp. 494-498 (May 2001).
Elbashir et al., “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate,” EMBO J., vol. 20(23), pp. 6877-6888 (Dec. 2001).
Finger et al., “Molecular phenotyping of human chondrocyte cell lines T/C-28a2, T/C-28a4, and C-28/l2,” Arthititis Rheum., vol. 48, pp. 3395-3403 (2003).
Galderisi et al., “Antisense Oligonucleotides as Therapeutic Agents,” J. Cell Physiol., vol. 181(2), pp. 251-257 (Nov. 1999).
Goekjian and Jirousek, “Protein kinase C inhibitors as novel anticancer drugs,” Expert. Opin. Investig. Drugs, vol. 10, pp. 2117-2140 (2001).
Heasman, “Morpholino Oligos: Making Sense of Antisense?,” Develop. Biol., vol. 243(2), pp. 209-214 (Mar. 2002).
Herbert et al., “Chelerythrine is a potent and specific inhibitor of protein kinase C,” Biochem. Biophys. Res. Commun., vol. 172, pp. 993-999 (1990).
Herget et al., “The myristoylated alanine-rich C-kinase substrate (MARCKS) is sequentially phosphorylated by conventional, novel and atypical isotypes of protein kinase C,” Eur. J. Biochem., vol. 233, pp. 448-457 (1995).
Hill et al. “Genomic Analysis of Gene Expression inC. elegans”, Science, vol. 290, pp. 809-812 (Oct. 2000).
Hussain et al., “Activation of Protein Kinase C ζ Is Essential for Cytokine-induced Metalloproteinase-1, -3, and -9 Secretion from Rabbit Smooth Muscle Cells and Inhibits Proliferation,” J. Biol. Chem., vol. 277, pp. 27345-27352 (2002).
Jordan et al., “Differential Effects of Protein Kinase C Inhibitors on Chemokine Production in Human Synovial Fibroblasts,” Br. J. Pharmacol., vol. 117, pp. 1245-1253 (1996).
Kim et al., “p38 kinase-dependent and -Independent inhibition of protein kinase C ζ and α regulates nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes,” J. Biol. Chem., vol. 277, pp. 30375-30381 (2002).
Knauert and Glazer, “Triplex Forming Oligonucleotides: Sequence-Specific Tools for Gene Targeting,” Hum. Mol. Genet., vol. 10(20), pp. 2243-2251 (2001).
Kochs et al., “Activation a
Arai Maya
Collins-Racie Lisa A.
LaVallie Edward R.
Dunston Jennifer
Fitzpatrick ,Cella, Harper & Scinto
Low Christopher S. F.
Wyeth
LandOfFree
Protein kinase C zeta as a drug target for arthritis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein kinase C zeta as a drug target for arthritis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase C zeta as a drug target for arthritis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4134991